Autolus Therapeutics/$AUTL
1D1W1MYTD1Y5YMAX
Capital at risk
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Ticker
- $AUTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 753
- Headquarters
- London, United Kingdom
- Website
- www.autolus.com
AUTL Metrics
BasicAdvanced
$516M
-
-$1.05
2.02
-
Price and volume
Market cap
$516M
Beta
2.02
52-week high
$2.58
52-week low
$1.18
Average daily volume
3M
Financial strength
Current ratio
4.886
Quick ratio
2.931
Long term debt to equity
4.665
Total debt to equity
4.915
Interest coverage (TTM)
-5.47%
Profitability
EBITDA (TTM)
-236.571
Gross margin (TTM)
-74.60%
Net profit margin (TTM)
-238.65%
Operating margin (TTM)
-210.49%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-25.44%
Return on equity (TTM)
-133.00%
Valuation
Price to revenue (TTM)
4.398
Price to book
6.9
Price to tangible book (TTM)
9.17
Price to free cash flow (TTM)
-2.144
Free cash flow yield (TTM)
-46.64%
Free cash flow per share (TTM)
-0.905
Growth
Revenue change (TTM)
292.16%
Earnings per share change (TTM)
20.46%
3-year revenue growth (CAGR)
150.30%
3-year earnings per share growth (CAGR)
-2.52%
Bulls say / Bears say
AUCATZYL® net product revenue reached $45.7 million in Q2 2026, a 119% increase year-over-year, underscoring strong commercial uptake of Autolus’ lead CAR-T therapy. (Autolus)
Autolus reported cash, cash equivalents and marketable securities of $201.6 million as of June 30, 2026, and expects this liquidity and proceeds from its credit facility to fund operations into Q2 2028, reducing near-term dilution risk. (SEC)
The company plans pipeline diversification with initial Phase 1 ALARIC light-chain amyloidosis data from AUTO8 by end-2026 and pediatric r/r B-ALL studies under FDA RMAT designation, supporting future growth beyond its ALL franchise. (GlobeNewswire; SEC)
Autolus incurred a Q2 2026 operating loss of $43.8 million and a net loss of $39.1 million, indicating continued high R&D and SG&A expenses relative to revenue. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
AUTL News
AllArticlesVideos
Funds containing AUTL
AllUSDGBP
Fund name | Fund size | $AUTL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.